Summary Mechanisms for improving photodynamic therapy (PDT) were investigated in the murine RIFI tumour using meso-tetrahydroxyphenylchlorin (m-THPC) 
Photodynamic therapy (PDT) has proved to be a useful treatment for several types of solid cancers in man. The photosensitiser currently in most widespread clinical use is Photofrin, of which the major adverse side-effect is accumulation of sensitiser in the skin, resulting in photosensitisation which can persist for 6-8 weeks (Dougherty et al., 1990) . Several new photosensitising agents have been developed, aiming at reduced skin photosensitisation, along with greater light absorbance at longer wavelengths. Mesotetrahydroxyphenylchlorin (m-THPC), absorption peak at 652 nm, has demonstrated excellent anti-tumour activity for low doses of both drug and light (Ris et al., 1991 (Ris et al., , 1993 Van Geel et al., 1995) . Large gains were seen for m-THPCmediated PDT in tumours compared with Photofrin, plus more rapid fading of skin photosensitisation. Bacteriochlorin a (BCA), a derivative of bacteriochlorophyll a, has also proven to be a very effective photosensitiser in vitro and in vivo (Schuitmaker et al., 1990 ). BCA has a major absorption peak at 760 nm, where tissue penetration is optimal. The penetration depth of light used to activate this photosensitiser, and thus the treated tumour volume, may therefore be maximised.
Tumour damage by PDT occurs either by direct tumour cell killing or, more importantly, by secondary cell killing effects induced after severe vascular damage and ischaemia (Henderson et al., 1985) . This phenomenon of vascular damage and induced hypoxia (Moore et al., 1993) occurring at very short intervals following treatment led to the use of PDT in conjunction with bioreductive drugs, which are specifically toxic to hypoxic cells. Such studies have demonstrated that PDT in combination with bioreductive drugs can give enhanced anti-tumour effect (Gonzalez et al., 1986; Bremner et al., 1992; Baas et al., 1994) .
The purpose of this study was to measure the influence of m-THPC-or BCA-mediated PDT on the vascular perfusion and tumour response (regrowth time, cures and in vitro cell survival) in subcutaneous RIFI tumours after in vivo PDT and to compare these results with Photofrin-mediated PDT. The vascular perfusion data were also required as a rational basis for the development of protocols involving combined PDT with the bioreductive agent mitomycin C (MMC).
Materials and methods

Animal models
All experiments were carried out in accordance with protocols approved by the local experimental animal welfare committee and conform to national and European regulations for animal experimentation. Female C3H/Km mice were used in all experiments, weighing [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] (Table II) . For tumour illuminations, the diffusing fibre tips were inserted through the centre of the tumours of unanaesthetised mice held in restraining jigs, as described by Baas et al. (1993) .
For BCA-PDT a pigtailed (fibre diameter 100 Lm multimode) diode laser (Philips), lasing at 750 nm maximum (output 200 mW), was used (Best et al., 1993 aSignificantly different from untreated control group (P <0.01).
with a 0.1 ml aliquot of the injection solution which was used as a standard. Four to six mice per group were used for these experiments. The tails were excised to check the residual activity at the site of the injection (5-10% of the injected dose in most mice) and the sample counts were corrected for radioactivity in the tail before calculating the percentage of injected dose in tumour or kidney. If the residual activity in the tail was 15% or more, the samples were excluded from analysis. Control groups receiving sensitiser alone, light alone (652 and 750 nm) or no treatment were also tested for tumour perfusion (Table III) .
In vivo/in vitro assay Tumours treated with Photofrin PDT or m-THPC PDT and control tumours treated with photosensitiser alone, light alone, MMC alone or receiving no treatment (Table IV) were excised under sterile conditions after cervical dislocation. Two tumours were pooled for each time point. For BCA PDT no in vivo/in vitro assays were performed because with this experimental set-up only one mouse could be treated per time point. The excised tumours were protected from direct light exposure, weighed, minced with scissors and placed into a flask containing protease (type IX), DNAse (type I) and collagenase (type IV) in 5 ml of sterile phosphate-buffered saline (PBS) and stirred at 37'C for 30 min to release tumour cells. The resulting suspension was then strained through a wire mesh to eliminate any remaining tissue clumps and cell aggregates. The cells were washed with Ham's F-10 medium containing antibiotics (penicillin 100 IU ml-' and streptomycin 100 g ml-') without serum and centrifuged for 5 min 346 at 1000 r.p.m. The supernatant was discarded and the cell pellet resuspended in 10 ml of Ham's F-10 medium containing antibiotics and 10% fetal calf serum. Cell numbers were determined with a Coulter counter, and after staining with trypan blue the percentage of dead cells was counted with a haemocytometer. Known numbers of viable cells were plated into Petri dishes at appropriate concentrations in Ham's F-10 medium containing antibiotics and 10% fetal calf serum for colony formation. After 6 days in a humidified 5% carbon dioxide incubator at 37°C, the cells were washed with saline (0.9%) and fixed and stained with glutaraldehyde (15%, w/w) and crystal violet (2%, w/w). Colonies containing >50 cells were then counted. The Coulter counter and haemocytometer counts yielded information from which viable cell yield per gram of tumour was calculated on the basis of total cell counts. Colony assays were used to determine the fraction of viable cells which were clonogenic. The significance of difference in vascular perfusion and clonogenicities for the control groups and treated groups was determined according to the non-parametric Kruskal-Wallis test; P-values of < 0.05 were considered significant. Kendall's tau correlation coefficient between vascular perfusion and tumour regrowth time was calculated from the group means for each photosensitiser; cured tumours were also taken into account in assessing significance.
The association of the different treatments with the regrowth time was analysed using non-parametric survival analysis methods. To study simultaneously the influence of photosensitiser, light and MMC on regrowth time, a Wilcoxon's proportional hazard model was adjusted using a step- 
Results
The tumour perfusion data are analysed as 86Rb counts per gram of tissue, expressed as a percentage of the injected activity (minus residual activity in the tail resulting from leakage at the injection site) (Figure 1 and Table III ). This gives a measure of the proportion of the cardiac output supplying that tissue. Light-alone (fibre insertion with light
,~~~~~~. It was clear from tumour perfusion experiments that all three photosensitisers induced a substantial reduction in perfusion for subcurative light doses. It has been suggested that transient PDT-induced hypoxia could be exploited to enhance the tumoricidal effects of bioreductive drugs which are specifically toxic against hypoxic cells (Gonzalez et al., 1986) . The effect of Photofrin or m-THPC PDT in combination with MMC was therefore also tested in the in vivo/in vitro experiments. MMC alone caused no more than a 4 day delay in tumour regrowth in vivo and reduced the surviving fraction to <1% when assayed by the in vivo-in vitro technique 24 h after injection (Table V) . Other experiments with MMC alone showed a 0.34% ± 0.24% surviving fraction when assayed 20 min after MMC injection. The unexpectedly low surviving fractions, in relation to the modest 4 days tumour regrowth time (Table II) , may have been due to the drug being carried over with the tumour into the dispersal medium and causing additional cell killing (Twentyman, 1977) . Untreated and MMC-treated tumour halves were therefore combined and tested for this. The killing artifact was apparently absent here, since the plating efficiency of the mixture could be adequately predicted from the separate plating efficiencies without invoking interactions. An alternative explanation is that cells are made sensitive to the killing action of MMC during dispersal (the number of living cells decreased from 93% control value to about 80%).
For Photofrin and m-THPC PDT in combination with MMC, the 24h time point is reliable since the half-life of MMC is 10-50 min under physiological conditions, therefore no free drug will be present at this time. Cell survival assessed 24h after equitoxic drug light schedules (15 days regrowth time), was significantly lower after PDT in combination with MMC than after PDT alone. Clonogenicities for Photofrin and m-THPC PDT in combination with MMC were 0.02% ± 0.003% and 0.3% ± 0.07% respectively. These values are consistent with additive cell killing from MMC and PDT. (Table II) . A small but significant increase in growth time occurred when the photosensitiser, fibre and/or light alone was given. MMC alone also induced a small, but significant, increase in tumour regrowth time. The combination of MMC with m-THPC, BCA or illumination (652 nm) was not significantly different from MMC alone.
BCA was tested in tumour regrowth studies in a concentration of 10-30 mg kg-', given 15 min or 1 h before light treatment (Figure 3) . When BCA was given 15 min before illumination, regrowth time was greater than with the 1 h time interval. BCA in a concentration of 30 mg kg-' given 15 min before light treatment was too toxic (1/3 deaths). The schedule of 20 mg kg-' given at 15 min before illumination was therefore chosen for further studies. Figure 4 shows the mean tumour regrowth times after the combined treatment of PDT and MMC compared with m-THPC or BCA PDT alone. The in vivo photosensitising ability of both drugs was compared with previously published results for Photofrin PDT with or without MMC (Baas et al., 1994 ; dashed lines in Figure 4 ). m-THPC-mediated PDT alone (Van Geel et al., and BCA in a concentration of 20 mg kg-' 15 min before illumination. Previously published Photofrin data (Baas et al., 1994) for regrowth time after PDT alone (--) or with MMC (-) are also indicated by the dashed lines. The data for m-THPC PDT were previously published (Van Geel et al., 1994 
TCD50d (J cm') (Baas et al., 1994) .
Discussion PDT can cause cell death both by direct disruption of the cellular membranes and organelles, e.g. mitochondria (Grossweiner, 1984) , and by damage to the tumour vasculature leading to secondary tumour cell death (Castellani et al., 1963; Bugelski et al., 1981; Star et al., 1986 (Baas et al., 1994) , where the maximum benefit from the combination MMC + PDT is obtained when the drug is given before illumination. This difference may be due to the higher light dose (400 J cm-') required for effective tumour treatment with Photofrin-mediated PDT. These light doses require 68 min for delivery, by which time vascular perfusion probably inhibits the access of MMC into the tumour (Van Geel et al., 1994 
